Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility

Jung Gi Lee, Jae Ha Ryu, Seon Myung Kim, Moon Young Park, San Ho Kim, Young G. Shin, Jong Woo Sohn, Ha Hyung Kim, Zee Yong Park, Jae Young Seong, Jae Il Kim

Research output: Contribution to journalArticle

5 Citations (Scopus)

Abstract

Exendin-4, a 39 amino acid peptide isolated from the saliva of the Gila monster, plays an important role in regulating glucose homeostasis, and is used clinically for the treatment of type 2 diabetes. Exendin-4 shares 53% sequence identity with the incretin hormone glucagon-like peptide 1 (GLP-1) but, unlike GLP-1, is highly resistant to proteolytic enzymes such as dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase 24.11 (NEP 24.11). Herein, we focused on the structure and function of the C-terminal Trp-cage of exendin-4, and suggest that it may be structurally required for resistance to proteolysis by NEP 24.11. Using a series of substitutions and truncations of the C-terminal Trp-cage, we found that residues 1–33, including the N-terminal and helical regions of wild-type (WT) exendin-4, is the minimum motif required for both high peptidase resistance and potent activity toward the GLP-1 receptor comparable to WT exendin-4. To improve the therapeutic utility of C-terminally truncated exendin-4, we incorporated various fatty acids into exendin-4(1–33) in which Ser33 was substituted with Lys for acylation. Exendin-4(1–32)K-capric acid exhibited the most well balanced activity, with much improved therapeutic utility for regulating blood glucose and body weight relative to WT exendin-4.

Original languageEnglish
Pages (from-to)59-68
Number of pages10
JournalBiochemical Pharmacology
Volume151
DOIs
Publication statusPublished - 2018 May 1

Fingerprint

Fatty Acids
Neprilysin
Glucagon-Like Peptide 1
Therapeutics
Peptide Hydrolases
Proteolysis
Dipeptidyl Peptidase 4
Incretins
exenatide
Acylation
Lizards
Medical problems
Saliva
Type 2 Diabetes Mellitus
Blood Glucose
Homeostasis
Substitution reactions
Body Weight
Hormones
Amino Acids

Keywords

  • Diabetes
  • Exendin-4
  • Fatty acid
  • GLP-1 receptor
  • Neutral endopeptidase 24.11

ASJC Scopus subject areas

  • Biochemistry
  • Pharmacology

Cite this

Lee, J. G., Ryu, J. H., Kim, S. M., Park, M. Y., Kim, S. H., Shin, Y. G., ... Kim, J. I. (2018). Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility. Biochemical Pharmacology, 151, 59-68. https://doi.org/10.1016/j.bcp.2018.03.004

Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility. / Lee, Jung Gi; Ryu, Jae Ha; Kim, Seon Myung; Park, Moon Young; Kim, San Ho; Shin, Young G.; Sohn, Jong Woo; Kim, Ha Hyung; Park, Zee Yong; Seong, Jae Young; Kim, Jae Il.

In: Biochemical Pharmacology, Vol. 151, 01.05.2018, p. 59-68.

Research output: Contribution to journalArticle

Lee, JG, Ryu, JH, Kim, SM, Park, MY, Kim, SH, Shin, YG, Sohn, JW, Kim, HH, Park, ZY, Seong, JY & Kim, JI 2018, 'Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility', Biochemical Pharmacology, vol. 151, pp. 59-68. https://doi.org/10.1016/j.bcp.2018.03.004
Lee, Jung Gi ; Ryu, Jae Ha ; Kim, Seon Myung ; Park, Moon Young ; Kim, San Ho ; Shin, Young G. ; Sohn, Jong Woo ; Kim, Ha Hyung ; Park, Zee Yong ; Seong, Jae Young ; Kim, Jae Il. / Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility. In: Biochemical Pharmacology. 2018 ; Vol. 151. pp. 59-68.
@article{ba51d4d4883b4b2589f9ea0a2c0eda72,
title = "Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility",
abstract = "Exendin-4, a 39 amino acid peptide isolated from the saliva of the Gila monster, plays an important role in regulating glucose homeostasis, and is used clinically for the treatment of type 2 diabetes. Exendin-4 shares 53{\%} sequence identity with the incretin hormone glucagon-like peptide 1 (GLP-1) but, unlike GLP-1, is highly resistant to proteolytic enzymes such as dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase 24.11 (NEP 24.11). Herein, we focused on the structure and function of the C-terminal Trp-cage of exendin-4, and suggest that it may be structurally required for resistance to proteolysis by NEP 24.11. Using a series of substitutions and truncations of the C-terminal Trp-cage, we found that residues 1–33, including the N-terminal and helical regions of wild-type (WT) exendin-4, is the minimum motif required for both high peptidase resistance and potent activity toward the GLP-1 receptor comparable to WT exendin-4. To improve the therapeutic utility of C-terminally truncated exendin-4, we incorporated various fatty acids into exendin-4(1–33) in which Ser33 was substituted with Lys for acylation. Exendin-4(1–32)K-capric acid exhibited the most well balanced activity, with much improved therapeutic utility for regulating blood glucose and body weight relative to WT exendin-4.",
keywords = "Diabetes, Exendin-4, Fatty acid, GLP-1 receptor, Neutral endopeptidase 24.11",
author = "Lee, {Jung Gi} and Ryu, {Jae Ha} and Kim, {Seon Myung} and Park, {Moon Young} and Kim, {San Ho} and Shin, {Young G.} and Sohn, {Jong Woo} and Kim, {Ha Hyung} and Park, {Zee Yong} and Seong, {Jae Young} and Kim, {Jae Il}",
year = "2018",
month = "5",
day = "1",
doi = "10.1016/j.bcp.2018.03.004",
language = "English",
volume = "151",
pages = "59--68",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Replacement of the C-terminal Trp-cage of exendin-4 with a fatty acid improves therapeutic utility

AU - Lee, Jung Gi

AU - Ryu, Jae Ha

AU - Kim, Seon Myung

AU - Park, Moon Young

AU - Kim, San Ho

AU - Shin, Young G.

AU - Sohn, Jong Woo

AU - Kim, Ha Hyung

AU - Park, Zee Yong

AU - Seong, Jae Young

AU - Kim, Jae Il

PY - 2018/5/1

Y1 - 2018/5/1

N2 - Exendin-4, a 39 amino acid peptide isolated from the saliva of the Gila monster, plays an important role in regulating glucose homeostasis, and is used clinically for the treatment of type 2 diabetes. Exendin-4 shares 53% sequence identity with the incretin hormone glucagon-like peptide 1 (GLP-1) but, unlike GLP-1, is highly resistant to proteolytic enzymes such as dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase 24.11 (NEP 24.11). Herein, we focused on the structure and function of the C-terminal Trp-cage of exendin-4, and suggest that it may be structurally required for resistance to proteolysis by NEP 24.11. Using a series of substitutions and truncations of the C-terminal Trp-cage, we found that residues 1–33, including the N-terminal and helical regions of wild-type (WT) exendin-4, is the minimum motif required for both high peptidase resistance and potent activity toward the GLP-1 receptor comparable to WT exendin-4. To improve the therapeutic utility of C-terminally truncated exendin-4, we incorporated various fatty acids into exendin-4(1–33) in which Ser33 was substituted with Lys for acylation. Exendin-4(1–32)K-capric acid exhibited the most well balanced activity, with much improved therapeutic utility for regulating blood glucose and body weight relative to WT exendin-4.

AB - Exendin-4, a 39 amino acid peptide isolated from the saliva of the Gila monster, plays an important role in regulating glucose homeostasis, and is used clinically for the treatment of type 2 diabetes. Exendin-4 shares 53% sequence identity with the incretin hormone glucagon-like peptide 1 (GLP-1) but, unlike GLP-1, is highly resistant to proteolytic enzymes such as dipeptidyl peptidase IV (DPP-IV) and neutral endopeptidase 24.11 (NEP 24.11). Herein, we focused on the structure and function of the C-terminal Trp-cage of exendin-4, and suggest that it may be structurally required for resistance to proteolysis by NEP 24.11. Using a series of substitutions and truncations of the C-terminal Trp-cage, we found that residues 1–33, including the N-terminal and helical regions of wild-type (WT) exendin-4, is the minimum motif required for both high peptidase resistance and potent activity toward the GLP-1 receptor comparable to WT exendin-4. To improve the therapeutic utility of C-terminally truncated exendin-4, we incorporated various fatty acids into exendin-4(1–33) in which Ser33 was substituted with Lys for acylation. Exendin-4(1–32)K-capric acid exhibited the most well balanced activity, with much improved therapeutic utility for regulating blood glucose and body weight relative to WT exendin-4.

KW - Diabetes

KW - Exendin-4

KW - Fatty acid

KW - GLP-1 receptor

KW - Neutral endopeptidase 24.11

UR - http://www.scopus.com/inward/record.url?scp=85043355234&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85043355234&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2018.03.004

DO - 10.1016/j.bcp.2018.03.004

M3 - Article

C2 - 29522713

AN - SCOPUS:85043355234

VL - 151

SP - 59

EP - 68

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

ER -